Inovio spinoff developing patient-specific cancer therapies raises $10.5M

Geneos Therapeutics, a Montgomery County cancer immunotherapy startup, has raised $10.5 million in a private stock sale according to documents filed with the Securities and Exchange Commission. The company was spun off from publicly traded Inovio Pharmaceuticals (NASDAQ: INO), which like Geneos is based in Plymouth Meeting. Niranjan Y. Sardesai has stepped down from his post as Inovio’s chief operating officer, to serve full time as CEO of Geneos. Geneos’s series A financing was led by Santé…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news